Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07368972 · ClinicalTrials.gov registry record · Phase 2
Study of DISC-0974-201 in Participants With IBD and Anemia
A Phase 2 study of Anemia and Inflammatory Bowel Disease (IBD), sponsored by Disc Medicine.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 21
- Enrollment target
- 5
- Study locations
NCT07368972: Recruiting Phase 2 study of Anemia and Inflammatory Bowel Disease (IBD), sponsored by Disc Medicine.
NCT07368972 is a Phase 2 study of Anemia and Inflammatory Bowel Disease (IBD) that is actively recruiting participants, run by Disc Medicine. The registered enrollment target is 21 participants, below the 427-participant average among 72 other Anemia trials with a reported enrollment target (95% lower). The trial reports 5 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07368972, a Phase 2 study of Anemia and Inflammatory Bowel Disease (IBD), is actively recruiting participants, sponsored by Disc Medicine.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 21 participants
- Enrollment target
- 5
- Study locations
Study Summary
This is a Phase 2, multicenter, randomized, double-blind placebo-controlled study of DISC-0974 to evaluate safety, tolerability, and efficacy in participants with IBD and anemia of inflammation.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG DISC-0974
Study Locations (5)
Florida
- Clinical Research of Osceola, LLC - Kissimmee
- Anchor Medical Research, LLC - Miami
- Guardian Angel Research, Inc - Tampa
Arizona
- One of a Kind Clinical Research Center, LLC - Scottsdale
Texas
- One of a Kind Clinical Research Center, LLC - Kingwood
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2026-02-20 |
| Est. Completion | 2027-03 |
| Phase | Phase 2 |
What NCT07368972 shows while recruiting
NCT07368972 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 21 participants, a relatively small participant target, below the 427-participant average among 72 other Anemia trials with a reported enrollment target (95% lower).
The record links to 3 conditions, with Anemia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07368972 lists 5 locations in 3 states (Florida, Arizona, Texas).
Frequently Asked Questions
What is clinical trial NCT07368972 about?
NCT07368972 is a clinical study titled "Study of DISC-0974-201 in Participants With IBD and Anemia". This is a Phase 2, multicenter, randomized, double-blind placebo-controlled study of DISC-0974 to evaluate safety, tolerability, and efficacy in participants with IBD and anemia of inflammation.
What is the current status of trial NCT07368972?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 21 participants. The study started on 2026-02-20. Estimated completion is 2027-03.
What conditions does trial NCT07368972 study?
This clinical trial studies the following conditions: Anemia, Inflammatory Bowel Disease (IBD), Inflammatory Bowel Disease (IBD); Anemia.
What interventions are being tested in trial NCT07368972?
The interventions under investigation include: Placebo (DRUG), DISC-0974 (DRUG).
Who is sponsoring clinical trial NCT07368972?
This trial is sponsored by Disc Medicine, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07368972 being conducted?
This trial has 5 study locations across Arizona, Florida, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Anemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07368972's enrollment target sits among peer trials
21 68th of 72 higher than 5 of 72 other Anemia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Anemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Luspatercept for Anemia in Lower Risk MDS or Non-proliferative MDS/MPN Neoplasms
RECRUITING · Phase 2
-
129Xe MRI Cardiopulmonary
RECRUITING · Phase 2
-
177Lu-PSMA-617 in Metastatic Castration Resistant Prostate Cancer (mCRPC) With Bone Marrow Involvement and Cytopenia
RECRUITING · Phase 2
-
Choline and Iron Deficiency
RECRUITING · Phase 2
-
Luspatercept for Clonal Cytopenias of Uncertain Significance
RECRUITING · Phase 2
-
Iron Replacement to Reduce Anemia During Neoadjuvant Chemotherapy
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02447874 · 21 participants · Phase 1
Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease
- NCT03826992 · 21 participants · Phase 1
Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
- NCT04107077 · 21 participants · Phase 2
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
- NCT04158635 · 21 participants · Phase 1
Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI